Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Telectronics

This article was originally published in The Gray Sheet

Executive Summary

Telectronics: Suspends U.S. product shipments under consent decree with FDA, firm announces May 19. According to Telectronics, the decree sets "specific steps" the firm must take to assure FDA that it is in compliance with good manufacturing practices regs. The agreement does not affect products already implanted or already shipped, or products for export outside U.S. Telectronics President Jim Dennis stresses that the decree "concerns manufacturing procedures only" and that the agency "has not alleged that any of the products currently marketed are defective in any way." The decree is unrelated to Accufix Atrial J Lead, which was subject to a safety alert in December 1994 and which Telectronics no longer produces ("The Gray Sheet" Jan. 2, p. 12)...

You may also be interested in...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts